Financial Highlights for Fourth Quarter 2022 Ended December 31, 2022 (Compared to the Fourth Quarter of 2021) Revenue increased 69% to $5.1 million from $3.0 million. Operating Loss improved significantly to $2.0 million loss compared to $4.6 million Operating Loss Net Loss in 2022 improved to $0.1 million loss compared to… Read More..

FRISCO, TX, April 20, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Verde Bio Holdings, Inc. (OTCQB: VBHI) (www.verdebh.com) today announced today that it has engaged a New York based investment banking firm to act as advisor, lead underwriter, and deal manager for any future public offering and simultaneous up-listing as… Read More..

TARRYTOWN, NY, April 19, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire –PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (“APT”) for the treatment of disorders with intractable neurologic symptoms, today announced that Chief Executive Officer Howard Weisman will ring the Nasdaq… Read More..